CareDx (CDNA) Stock Forecast & Price Target

CareDx is attractive fundamentally because its core transplant testing franchise is growing strongly, with Q2’26 revenue of $132M (+52% Y/Y), core test revenue of $100M (+61% Y/Y), and volume growth of 17%, while improved revenue-cycle management and higher ASPs are lifting profitability. The final transplant LCD materially reduced reimbursement risk, preserved the HeartCare bundle and for-cause testing, and left room for years of volume growth because current utilization sits below the new limits. In addition, the Naveris acquisition adds a faster-growing, higher-margin oncology MRD business that management expects to grow 30%-40% annually, reinforcing a more diversified, higher-quality growth profile.

CareDx is challenged by a growth strategy that depends on successfully commercializing new diagnostic solutions, yet that process requires heavy R&D spending, clinical validation, clinician and laboratory acceptance, and approvals that can take years and fail. Adoption risk is elevated because clinicians and healthcare administrators may resist changing historical practices, especially when liability and reimbursement uncertainties slow uptake of AlloSure Kidney, AlloMap Heart, AlloSure Heart, and AlloSure Lung. These issues matter because the company generates most of its revenue from testing services in the United States, and recent LCD-related concerns highlighted the vulnerability of transplant utilization, with management citing a possible $15-30M annualized revenue headwind.